The Board of Directors of Gufic Biosciences has approved the re-appointment of Pankaj Jayakumar Gandhi as Whole Time Director for a further term of five years. The decision, taken during a board meeting on July 31, 2026, secures leadership continuity for the pharmaceutical company through September 06, 2031. The re-appointment is subject to approval by shareholders at the ensuing 42nd Annual General Meeting.

The appointment was made pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board also confirmed compliance with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Mr. Gandhi is not debarred from holding the office of Director by any order passed by the Securities and Exchange Board of India (SEBI) or any other authority.

Key Appointment Details

Leadership Profile

Pankaj Jayakumar Gandhi holds a Bachelor's degree in Commerce from the University of Mumbai. He brings over three decades of experience in liaising with regulatory authorities within the pharmaceutical industry. His role focuses on ensuring regulatory compliance and maintaining effective coordination with statutory bodies. Management notes that his expertise has contributed significantly to the operational efficiency of Gufic Biosciences.

Regulatory Compliance

The company disclosed that Mr. Gandhi is not related to any other Directors of the Company. The Board meeting commenced at 04:30 p.m. and concluded at 06:25 p.m. on July 31, 2026. The announcement was signed by Ami Shah, Company Secretary & Compliance Officer (Membership No. A39579).

Gufic Biosciences has reported its financial results for the fourth quarter and financial year ended March 31, 2026. The company recorded its strongest quarterly revenue of INR252 crore in Q4FY26, a jump of over 15% from INR205 crore in the previous year. Profit after tax (PAT) for the quarter more than doubled to INR20.5 crore from INR8 crore in Q4FY25. For the full year FY26, revenue stood at INR940.50 crore, while PAT was INR63.2 crore. The management attributed the performance to a strong Q4, operational improvements, and strategic shifts in the business model.

Financial Performance

The company's EBITDA for Q4FY26 rose to INR44.7 crore, up from INR27 crore in the corresponding period of the previous year, with the EBITDA margin expanding to 17.73% from 13.17%. For the full year FY26, EBITDA was INR152.9 crore on a revenue of INR940.50 crore. The table below summarises the key financial metrics for the quarter and the full year:

Management Guidance

During the earnings conference call, management provided guidance for the coming years. The company targets a revenue growth of 15% year-over-year. On the profitability front, the EBITDA margin for FY27 is expected to be around 18%, with an annual improvement of 0.50% to 1% anticipated thereafter. By 2030, the company aims to achieve EBITDA margins exceeding 20%.

Gross margins are also projected to improve by 0.50% to 1% annually, driven by product mix optimisation, geography mix, and pricing strategies. The company expects gross debt to remain around INR400 crore to support working capital requirements for top-line growth.

Capital Expenditure and Operational Updates

The management stated that no greenfield capital expenditure is foreseen for the next two years. However, replacement CapEx of approximately INR20 crore annually is planned to ensure business continuity. The Indore facility, which reached 30% capacity utilisation in Q4FY26, has achieved EBITDA breakeven. The company has completed 40 product tech transfers at this facility, with another 27 under development.

On the international business front, the company is transitioning from a distributor-led model to holding marketing authorizations directly, which it expects will enhance margins. New product approvals were received in markets including Myanmar, the Philippines, South Africa, Colombia, Germany, and Ecuador. Additionally, the company signed an in-licensing agreement with a Canadian aesthetics company for fillers to complement its botulinum toxin portfolio in India.